TLR4 Agonist Composition for Preserving Organ Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies are ineffective for treating chronic organ diseases or preventing loss of organ function due to acute organ dysfunction, and existing formulations of MPLA-like compounds face challenges such as injection site pain, lack of bioavailability, and stability issues.
Innovation Solution
Compositions and methods using MPLA-like compounds, particularly TLR4 agonists, are administered to redirect the innate immune response from a pro-inflammatory to an anti-inflammatory state, thereby preventing or treating chronic organ diseases and acute organ stress by stimulating the TRIF pathway to produce anti-inflammatory cytokines.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MPLA-like compounds are formulated to improve biologic activity, then therapeutic efficacy is improved, but formulation stability and ease of administration deteriorate due to hydrophobic nature requiring specialized equipment
Solution Approach 1:
The patent introduces a cosurfactant as an intermediary substance that facilitates the formulation of hydrophobic MPLA-like compounds in aqueous solutions. The cosurfactant acts as a mediator between the hydrophobic compound and water-based biological systems, enabling stable formulation without requiring specialized equipment while maintaining biologic activity.
Solution Approach 2:
The patent modifies the physical-chemical parameters of the MPLA-like compound formulation by incorporating a cosurfactant, which changes the solubility and stability parameters of the hydrophobic compound. This parameter change enables the compound to be formulated in aqueous solutions suitable for standard parenteral administration while preserving its biological efficacy.
2Reliability
If MPLA-like compounds are administered to treat chronic organ disease, then organ function is preserved, but injection site reactions and pain occur
Solution Approach 1:
The patent changes the formulation parameters by incorporating a cosurfactant that modifies the physical properties of the MPLA-like compound. This parameter change reduces the formulation's ability to cause injection site reactions and pain while maintaining the therapeutic efficacy of the compound in treating chronic organ disease.
3Reliability
If MPLA-like compounds are administered to prevent organ dysfunction, then organ function is preserved, but bioavailability is reduced
Solution Approach 1:
The cosurfactant serves as an intermediary that enhances the bioavailability of the hydrophobic MPLA-like compound by facilitating its dissolution and absorption in the biological system. This intermediary substance ensures that sufficient quantities of the active compound reach the target organ while maintaining therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively slows or halts the progression of organ damage by rebalancing the immune response, reducing pro-inflammatory cytokines, and producing anti-inflammatory cytokines, thus preserving organ function.
Implementation Method 1
Stimulation of toll-like receptor 4 (TLR4), can activate one of two pathways: 1) the Myeloid differentiation primary response 88 (MyD88) pathway, which leads to the production of pro-inflammatory cytokines, and 2) the TIR-domain-clustering adapter-inducing interferon-β (TRIF) pathway which leads to the production of anti-inflammatory protective cytokines and type I interferons
Implementation Method 2
Redirection of the innate immune response from a pro-inflammatory state to an anti-inflammatory (or non-inflammatory, protective) state will rebalance the innate immune response to slow down or halt the progressive destruction and scarring of organ tissue
Data Source
AI summary
The present disclosure provides methods for treating or preventing loss of organ function due to chronic organ or tissue diseases by administering to a subject an effective amount of a TLR4 agonist, such as an MPLA-like compound. More particularly, the present disclosure provides methods for preventing loss of kidney function due to chronic kidney disease, methods for preventing loss of organ function due to acute stress, and methods for preventing loss of kidney function due to acute stress by administering to a subject an effective amount of a TLR4 agonist. Also provided are pharmaceutical compositions comprising a TLR4 agonist that are useful for carrying out the aforesaid methods.